Supplementary Information

Interaction Energetics and Druggability of the Protein-Protein Interaction between Kelchlike ECH-associated Protein 1 (KEAP1) and Nuclear Factor, Erythroid 2 Like 2 (Nrf2)

Mengqi Zhong¹, Andrew Lynch¹, Stefan Jehle^{1,2}, Lingqi Luo^{2,3}, David R. Hall⁴, Reina Iwase¹, James P. Carolan¹, Kristina Streu¹, Christine M. Harvey¹, Dima Kozakov^{5,*}, Sandor Vajda^{1,2,3,6,*}, Karen N. Allen^{1,3,6,*} and Adrian Whitty^{1,6,*}

Supplementary Figures

Supplementary Figure S1: Characterization data for the KEAP1 protein constructs used in this study. *(SDS-PAGE, CD, thermal melting).*

Supplementary Figure S2: Characterization data for the Nrf2 protein constructs used in this study. *(SDS-PAGE, CD, thermal melting).*

Supplementary Figure S3: Inhibition data for $Nrf2_{1-100}$ and $Nrf2_{34-100}$, measured using the fluorescence anisotropy competition binding assay.

Supplementary Figure S4: Intramolecular interactions involving D77 and T80.

Supplementary Figure S5: New crystal from of KEAP1 b-propeller domain suitable for ligand soaking, and comparison of soaked structures of wild-type (LDEETGEFL) and T80A (LDEEAGEFL) 9-mer peptides.

Supplementary Figure S6: Sequence alignment of Nrf2 paralogs, and sequence conservation of key residues in KEAP1.

Supplementary Figure S7: Minor conformational change of Tyr525 upon ligand binding.

Supplementary Figure S8: Close-up view showing how R415 shifts upon ligand binding and the resulting effects on the relative strengths and locations of FTMap hot spots.

Supplementary Figure S9: Illustration showing how hot spot A can be approached to achieve higher binding affinity, using as an example Biogen compound 16.

Supplementary Tables

Supplementary Table 1: Extent of surface area that is buried by each residue in the DxETGE motif, upon binding to KEAP1, and the degree of overlap of each side-chain with the FTMap Consensus Clusters.

Supplementary Table 2: Fragment hits, with chemical structures and results observed in ThermoFluor and FA screening assays.

Supplementary Table 3: Locations and strengths of Consensus Clusters Apo and peptide-bound KEAP1 structures, and correlation with hot spots identified by alanine scanning.

Supplementary Table 4: List of Arg415 poses in 5 our structures, 17 human KEAP1 structures, and 3 co-crystal structures of Astex fragments bound mouse KEAP1.

Supplementary Table 5: Categorization of alanine scanning results into True Positive, False Positive, True Negative, False Negative, and Null results, plus correspondence with FTMap hot spots.

Supplementary Table 6. Crystallographic data collection and refinement statistics.

Figure S1. Characterization of KEAP1312-624 construct. (A) SDS-PAGE analysis of the KEAP1312-624 construct used in the study, under reducing and denaturing conditions. The intact mass of the protein was confirmed by ESI-qTOF mass spectrometry (not shown). (B) Thermal denaturation curve of KEAP1312-624 using the ThermoFluor method, monitored by the change of fluorescence signal at 480 nm of SYPRO Orange dye. Data are representative of three independent experiments. Inset shows the first derivative of the melting curve. The T_m value for KEAP1312-624 is 48.4 °C. (C) The Circular Dichroism spectrum of KEAP1312-624 in 25 mM Tris, pH 8.0 revealed a β-sheet secondary structure content. The program CDSSTR provided by DichroWeb was used to deconvolute the CD spectrum (dashed line). (D) Thermal denaturation data of KEAP1312-624 using CD, monitored by the change in θ203. Data are representative of two independent experiments. Inset shows the first derivative of the melting curve. The T_m value for KEAP1312-624 construct determined by CD is 44.2 °C. The thermal denaturation process is irreversible.

Figure S2. Characterization of Nrf234-100 constructs. (A) SDS-PAGE analysis of the Nrf234-100 constructs used in the study, under reducing and denaturing conditions. The intact mass of each protein was confirmed by ESI-qTOF mass spectrometry (not shown), showing that the small differences in apparent MW seen for some of the Nrf2 variants is a gel artifact. (B) Circular Dichroism spectrum of Nrf2 $_{34-100}$ in 20 mM phosphate, 200 mM NaCl, pH 7.4 at 10 °C (blue line), after being heated to 90 \degree at 1 \degree C/min (red dashed line), and after being incubated at 90 \degree for 30 min and then cooled back to 10 $\mathbb C$ at 1 $\mathbb C$ /min (green line). (C) Thermal denaturation of Nrf234-100 using CD, monitored by the change in θ208. Data are representative of two independent experiments. No cooperative unfolding transition was observed.

Figure S3. Comparison of the KEAP1 binding properties of Nrf21-100 versus Nrf234-100. Nrf21-100, which contains both the DLG and the DxETGE motifs (red), was evaluated in the FA competition assay in parallel with Nrf234-100 (blue), which contains DxETGE but not DLG. Anisotropy values were normalized to reflect the fractional changes between maximum and minimum anisotropy signal. Error bars show the range of duplicate experiments. Data were fitted to a competitive equilibrium binding model using DYNAFIT 4 software, as described in Materials and Methods (main text). The fits returned binding affinities of $K_D = 10 \pm 2$ nM for Nrf2₃₄₋₁₀₀ and 10 ± 1 nM for Nrf2₁₋₁₀₀. Results shown are representative of at least three independent experiments.

Figure S4. Intramolecular interactions involving D77 and T80 (dashed yellow lines indicate likely polar interactions). **A.** View of the bound Nrf2 peptide (white sticks), from a perspective looking down into the KEAP1 binding site (wheat surface). **B.** Peptide alone, viewed as looking from the bottom of the KEAP1 binding site (approximately a 180° vertical rotation from the view in A). Figures were created using the KEAP1/Nrf2 peptide structure from PDB 4IFL, with portions of the bound peptide lying outside the segment 76-LDEETGEF-83 omitted for clarity.

Supplementary Figure S5

Figure S5. New crystal from of KEAP1 β -propeller domain suitable for ligand soaking. A. Crystallographic dimer seen in our new crystal form (purple), compared with the previously reported structure 3ZGD (wheat). In our structure, the blade 2 BC-loop of chain B interacts with the DA loop between blades 1 and 2 of chain A. This difference in interaction, compared to previous KEAP1 structures, results in a shifting of chain B away from the chain A ligand binding site, fully opening the chain A ligand binding site to the solvent channel. **B.** X-ray crystal structure obtained by soaking KEAP1 crystals with the 8-mer LDEETGEF from PDB 4IFL (white) and 2FLU (green), peptide (yellow) superimposed with the corresponding regions of published co-crystal structure of Nrf2 bound to KEAP1, showing that the Nrf2-derived peptide maintains the same binding pose and thus that the crystal form used in these studies is suitable for fragment-soaking experiments. **C.** X-ray crystal structure of an Nrf2-derived 9-mer peptide that contains a T80A substitution (LDEEAGEFL), soaked into our new crystal form of KEAP1, superimposed on the soaked wild-type structure (white sticks), showing that the binding mode of the core ETGE motif residues is largely unchanged by the T80A mutation. **D**. Histogram showing how crystallographic B-factors for each residue of the bound T80A mutant peptide from (C), averaged over all residue atoms, increase towards the termini, whereas they remain constant for the wild-type peptide. A similar trend was seen for main-chain atoms only.

Figure S7. KEAP1 residue Tyr525 shows only minor conformattional adjustment to ligand binding. The side chains of Tyr525 and, for comparison, the highly mobile residue Arg415 in unbound KEAP1 (wheat), and in a published structure of KEAP1 bound by a small molecule (light pink, PDB 5FNU). Among the 17 reported crystal structures of human KEAP1 and 16 of mouse KEAP1, including unbound and liganded, only minor conformational shifts in Tyr525, such as shown above, are seen.

Figure S8. The repositioning of KEAP1 residue R415 upon Nrf2 binding indicates an induced fit component to the KEAP1/Nrf2 interaction. R415 conformations (sticks), relative position and strength of hot spot ^B and ^C (lines) in (**A**) unbound KEAP1 and (**B**) Nrf2 bound KEAP1 crystal structures. Upon ligand binding, the R415 side-chain moves into ^a position enabling the formation of ^a salt bridge with E79, shifting the locations of key hot spots B and C to achieve substantially greater overlap with the side-chain methyl group of T80.

Figure S9. Example of reported small molecule inhibitor that approaches hot spot A to position an aromatic moiety close to this strong hot spot. KEAP1 shown in wheat surface, compound shown in sticks (yellow), FTMap hot spots shown in lines.

Supplementary Table 1: Extent of contact with KEAP1 and overlap with FTMap hot spots, for each residue in the Nrf2 binding motif

¹Burial of solvent-accessible surface area in the KEAP1/Nrf2 complex (4IFL) attributable to the Nrf2 residue in question, calculated using PyMol as described in Materials and Methods. ²Overlap numbers represent the average of values calculated from FTMap analysis of unbound KEAP1 (3ZDG, chain A) and bound KEAP1 (4IFL, chain x) after removal of the atoms of Nrf2. ³Buried of solvent-accessible surface area attributable to all atoms of the residue in question. ⁴Burial of solvent-accessible surface area attributable to the side-chain atoms beyond Cβ; i.e. those atoms eliminated when the residue is mutated to alanine. ⁵Specific side-chain atoms that were used to calculate overlap with FTMap hot spots. ⁶Overlap with FTMap hot spots, summed for all side-chain atoms that were evaluated.

Supplementary Table 2: Table showing fragment hits, with chemical structures and results observed in ThermoFluor and FA assays.

 \overline{a}

^{*} ZT0707 was excluded from the soaking attempts because it contains two unmodified carboxylates, which is structurally unlikely to be a good hit.

Supplementary Table 3. Consensus clusters analysis on both Apo and peptide-bound KEAP1 structure

PDB ID Ligand R415 pose References Unbound
KEAP1 kEAP1 | No No Down | / Nrf2 9mer peptide bound LDEETGEFL Side / KEAP1 Ω ZT0256-bound EAP1 $\left[\begin{array}{ccc} 1 & 0 \\ 0 & 1 \end{array}\right]$ of Side $\left[\begin{array}{ccc} 0 & 0 \\ 0 & 1 \end{array}\right]$ O $NH₂$ ZT0017-bound $KEAP1$ N' N' N Side N н HO Down ZT0633-bound / (two side KEAP1 O: chain poses) ÒН 1U6D | No No Down 1ZGK | No | Down | (1) 2FLU AFFAQLQLDEETGEFL Down (2) $N-N$ O Ω 3VNG *(co-crystalized)* OН Down (3) 3VNH *(soaking)* 3ZGC | Cyclic GDEETGE | Side | (4) 3ZGD | No | Down | (4) 4IFJ No Down

Supplementary Table 4. Variable Arginine 415 poses in different reported crystal structures of KEAP1

Astex Fragments Bound Mouse KEAP1

Supplementary Table 5. Categorization of alanine scanning mutagenesis results on Nrf2

*T80 is a true positive in a qualitative but not in a quantitative sense, in that the alanine scanning result correctly identified a hot spot, but the magnitude of the loss of binding energy observed upon mutating T80 was amplified by indirect effects (see main text).

Supplementary Table 6. Crystallographic data collection and refinement statistics.

Statistics for the highest-resolution shell are shown in parentheses.

* Friedel mates were averaged when calculating reflection statistics.

References

- 1. Beamer LJ, Li XC, Bottoms CA, & Hannink M (2005) Conserved solvent and side-chain interactions in the 1.35 angstrom structure of the Kelch domain of Keap1. *Acta Crystallogr D* 61:1335-1342.
- 2. Lo SC, Li XC, Henzl MT, Beamer LJ, & Hannink M (2006) Structure of the Keap1 : Nrf2 interface provides mechanistic insight into Nrf2 signaling. *Embo J* 25(15):3605- 3617.
- 3. Satoh M*, et al.* (2015) Multiple binding modes of a small molecule to human Keap1 revealed by X-ray crystallography and molecular dynamics simulation. *Febs Open Bio* 5:557-570.
- 4. Horer S, Reinert D, Ostmann K, Hoevels Y, & Nar H (2013) Crystal-contact engineering to obtain a crystal form of the Kelch domain of human Keap1 suitable for ligand-soaking experiments. *Acta Crystallogr F* 69:592-596.
- 5. Marcotte D*, et al.* (2013) Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism. *Bioorgan Med Chem* 21(14):4011- 4019.
- 6. Jnoff E*, et al.* (2014) Binding Mode and Structure-Activity Relationships around Direct Inhibitors of the Nrf2-Keap1 Complex. *Chemmedchem* 9(4):699-705.
- 7. Jain AD*, et al.* (2015) Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators. *Eur J Med Chem* 103:252-268.
- 8. Davies TG*, et al.* (2016) Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery. *J Med Chem* 59(8):3991-4006.